Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 18/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14687856 | 1.00 | F2R (0.49) | F2RMAP4K4CHEK2 | |
| SCHEMBL2555787 | 0.85 | F2R (0.49) | F2RMAP4K4 | |
| SCHEMBL12285172 | 0.83 | F2R (0.43) | F2RMAP4K4 | |
| SCHEMBL8233042 | 0.79 | F2R (0.49) | F2RMAP4K4 | |
| SCHEMBL13915492 | 0.78 | F2R (0.41) | F2R | |
| SCHEMBL8274603 | 0.77 | F2R (0.44) | F2R | |
| SCHEMBL17503327 | 0.76 | F2R (0.44) | F2RMAP4K4 | |
| SCHEMBL25398241 | 0.75 | F2R (0.49) | F2R | |
| SCHEMBL2327132 | 0.72 | WNT3A (0.47) | F2RMAP4K4CHEK2 | |
| SCHEMBL16499011 | 0.71 | TAAR1 (0.52) | MAP4K4CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2558465-B1 | TRICYCLIC PYRIDYL-VINYL-PYROLES AS PAR1 INHIBITORS | SANOFI SA (FR) | 2014-12-17 | — | — | EP | disclosed |
| EP-2558465-B1 | TRICYCLIC PYRIDYL-VINYL-PYROLES AS PAR1 INHIBITORS | SANOFI SA (FR) | 2014-12-17 | — | — | EP | disclosed |
| US-8871798-B2 | Tricyclic pyridyl-vinyl pyrroles as PAR1 inhibitors | SANOFI (FR) | 2014-10-28 | — | — | US | disclosed |
| US-8871798-B2 | Tricyclic pyridyl-vinyl pyrroles as PAR1 inhibitors | SANOFI (FR) | 2014-10-28 | — | — | US | disclosed |
| US-8871798-B2 | Tricyclic pyridyl-vinyl pyrroles as PAR1 inhibitors | SANOFI (FR) | 2014-10-28 | — | — | US | disclosed |
| EP-2558462-B1 | Pyridyl-vinyl-pyrazolo-chinolines as PAR1 inhibitors | SANOFI SA (FR) | 2014-10-22 | — | — | EP | disclosed |
| EP-2558462-B1 | Pyridyl-vinyl-pyrazolo-chinolines as PAR1 inhibitors | SANOFI SA (FR) | 2014-10-22 | — | — | EP | disclosed |
| US-8791133-B2 | Pyridylvinylpyrazoloquinolines as PAR1 inhibitors | SANOFI (FR) | 2014-07-29 | — | — | US | disclosed |
| US-8791133-B2 | Pyridylvinylpyrazoloquinolines as PAR1 inhibitors | SANOFI (FR) | 2014-07-29 | — | — | US | disclosed |
| US-8791133-B2 | Pyridylvinylpyrazoloquinolines as PAR1 inhibitors | SANOFI (FR) | 2014-07-29 | — | — | US | disclosed |
| EP-2558465-A1 | TRICYCLIC PYRIDYL-VINYL PYRROLES AS PAR1 INHIBITORS | SANOFI (FR) | 2013-02-20 | — | — | EP | disclosed |
| EP-2558462-A1 | PYRIDYL-VINYL PYRAZOLOQUINOLINES AS PAR1 INHIBITORS | SANOFI (FR) | 2013-02-20 | — | — | EP | disclosed |
| US-20130040981-A1 | Pyridylvinylpyrazoloquinolines as PAR1 inhibitors | SANOFI (FR) | 2013-02-14 | — | — | US | disclosed |
| US-20130040943-A1 | TRICYCLIC PYRIDYL-VINYL PYRROLES AS PAR1 INHIBITORS | SANOFI (FR) | 2013-02-14 | — | — | US | disclosed |
| US-20130040943-A1 | TRICYCLIC PYRIDYL-VINYL PYRROLES AS PAR1 INHIBITORS | SANOFI (FR) | 2013-02-14 | — | — | US | disclosed |
| US-20130040981-A1 | Pyridylvinylpyrazoloquinolines as PAR1 inhibitors | SANOFI (FR) | 2013-02-14 | — | — | US | disclosed |
| US-20130040943-A1 | TRICYCLIC PYRIDYL-VINYL PYRROLES AS PAR1 INHIBITORS | SANOFI (FR) | 2013-02-14 | — | — | US | disclosed |
| US-20130040981-A1 | Pyridylvinylpyrazoloquinolines as PAR1 inhibitors | SANOFI (FR) | 2013-02-14 | — | — | US | disclosed |
| WO-2011128420-A1 | PYRIDYL-VINYL PYRAZOLOQUINOLINES AS PAR1 INHIBITORS | SANOFI (FR) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011128421-A1 | TRICYCLIC PYRIDYL-VINYL PYRROLES AS PAR1 INHIBITORS | SANOFI (FR) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040981-A1 | Pyridylvinylpyrazoloquinolines as PAR1 inhibitors | F2R, F2RL1, F2RL3 | F2R 1/4885MAP4K4 1280/4885CHEK2 1683/4885 |
| US-20130040943-A1 | TRICYCLIC PYRIDYL-VINYL PYRROLES AS PAR1 INHIBITORS | F2R, F2RL1, F2RL3 | F2R 1/4885MAP4K4 2257/4885CHEK2 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.